A common NKCC2 mutation in Costa Rican Bartter's syndrome patients : evidence of a founder effect by Kurtz, C.L. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/25474
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
A Common NKCC2 Mutation in Costa Rican Banter’s 
Syndrome Patients: Evidence for a Founder Effect
C. LISA KURTZ,* LOTHAR KAROLYI,+i HANNSJORG W 
MANUELA C. KOCH,1, ROSA VARGAS,§ DELPHINE FELDMANN,
*
KNOERS,# GILBERT MADRIGAL,** and
WOODFORD*ft
* Department o f  Medicine and ffDepartment o f  Pediatrics, University o f  Alabama at Birmingham, Birmingham 
Alabama; *Medical Center o f  Human Genetics and *Department of Pediatrics, Philipps University, Marburg, 
Germany; I^nstitut National de la Santé et de la Recherche Médicale U423, Necker Hospital, Paris, France;
^Department o f  Biochemistry, Armand-Trousseau Hospital, Paris, France; ^Department o f  Pediatrics, 
University of Freiburg, Freiburg, Germany; *Department of Human Genetics, University o f  Nijmegen, 
Nijmegen, The Netherlands; and **Hospital Nacional de Ninos, San Jose, Costa Rica,
Abstract. Bartter’s syndrome involves an overlapping set of 
closely related renal tubular disorders that can be subdivided 
into at least three clinical phenotypes; (7) the hypercalciuric 
antenatal Bartter variant; (2) the classic Bartter variant; and (5) 
the hypocalciuric-hypomagnesemic Gitelman variant. Recent 
data demonstrate that in several phenotypically indistinguish­
able cohorts, antenatal Bartter’s syndrome is genetically het­
erogeneous. In these patients, mutations in the genes encoding 
either the bumetanide-sensitive Na-K-2C1 cotransporter 
(NKCC2) or the ATP-regulated potassium channel ROMK
(KCNJ1) have been identified. A cohort of 20 Costa Rican 
patients with a congenital syndrome that bears strong similar­
ities to antenatal Bartter’s syndrome but also has several dis­
tinct features has recently been described. In this cohort, we 
have identified a predominant mutation that introduces a pre­
mature stop in codon W625 of the NKCC2  gene (SCL12A1), 
This mutant allele is contained on a single common haplotype, 
suggesting that the majority of antenatal Bartter’s syndrome 
patients in Costa Rica share a single common ancestor. (J Am 
Soc Nephrol 8: 1706-1711, 1997)
Data from numerous clinical studies indicate that Bartter’s 
syndrome involves an overlapping set of closely related renal 
tubular disorders that share as common features hypokalemia, 
metabolic alkalosis, and hyper-reninemic hyper aldosteronism 
with normal blood pressure (1). Within this relatively rare set 
of disorders, familial cases occur commonly and inheritance 
best fits with autosomal recessive transmission (2,3). These 
disorders can be subdivided into at least three clinical pheno­
types: (7) the antenatal hypercalciuric variant associated with 
severe systemic manifestations; (2) the classic syndrome orig­
inally described by Bartter et a l \  and (3) the hypocalciuric- 
hypomagnesemic variant described by Gitelman et al. (3-6).
In contrast to classic Bartter’s syndrome and Gitelman syn­
drome, the antenatal variant of Bartter’s syndrome typically 
presents as a life-threatening disorder that is characterized by 
both renal tubular hypokalemic alkalosis and profound sys­
temic manifestations (5,7). The disorder is first manifest in 
utero, with marked fetal polyuria, secondary polyhydramnios, 
and premature delivery (5,8-10). In affected neonates, the
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clinical hallmarks are severe salt wasting and hyposthenuria, 
moderate-to-severe hypokalemic metabolic alkalosis, hyper- 
prostaglandinuria, and failure to thrive. As a consequence of 
marked hypercalciuria, affected infants usually develop 
nephrocalcinosis and osteopenia (11-14). The fever, vomiting, 
and occasional diarrhea commonly associated with this disor­
der have been attributed to increased prostaglandin E2 activity. 
Accordingly, the term hyperprostaglandin E syndrome has 
been used for this antenatal variant of Bartter’s syndrome (7).
Recent studies have demonstrated that antenatal Bartter’s 
syndrome is genetically heterogeneous. Mutations in the genes 
encoding either the luminal bumetanide-sensitive Na-K-2C1 
cotransporter (NKCC2) or the luminal, ATP-regulated potas­
sium channel ROMK (.KCNJ1) have been described (15-17). 
In general, these patients share a common clinical phenotype, 
and the genetic data indicate that the molecular pathogenesis in 
these patients involves a primary defect in chloride transport 
across the medullary thick ascending limb (mTAL). However, 
in at least one other cohort of infants with a phenotypic variant 
of antenatal Bartter’s syndrome, both N KCC2  and KCNJ1 have 
been excluded as candidate disease susceptibility genes 
(18,19).
We have recently described the clinical characteristics of 20 
Costa Rican patients with a congenital syndrome that resem­
bles antenatal Bartter’s syndrome (20). These patients were 
identified over a 22-yr period in the Hospital Nacional de 
Ninos of Costa Rica, a 350-bed pediatric teaching hospital for
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a referral population of 3.3 million people. In the subset of 
patients that was available for genetic analyses, we identified a 
predominant mutation that introduces a premature stop in 
codon W625 of the N KCC2  gene (SCL12A1). This mutant 
allele is contained on a single common hapiotype. In the 
absence of consanguinity, these findings suggest that there is a 
founder effect in this population. That is, the majority of 
antenatal Bartter’s syndrome patients in Costa Rica appear to 
share a single common ancestor.
Materials and Methods
Patients
Index cases from families AB.CR1, AB.CR2, AB.CR3, and 
AB.CR4, as well as the sporadic cases AB.CRS1, AB.CRS2, and 
AB.CRS3, have been reported previously (17,20)
Genotype Analysis and Hapiotype Construction
Genomic DNA was isolated from all affected individuals and the 
available family members, using standard methods. Markers that are 
tightly linked to the NKCC2 gene on chromosome 15 were typed in 
each family, as well as in two of the three sporadic cases. The markers 
D15S143 through D15S123 are located on the yeast artificial chro­
mosome (YAC) 956E3 clone (CEPH library) (21). Previous analyses 
have confirmed that this YAC also contains the NKCC2 gene (17). An 
additional, tightly linked marker, D15S126, was selected from the 
Genethon data base (accessible at http://www.genethon.fr/genetho~ 
n_en.html). The order D15S143-DI5S123-D15D126 has been estab- 
lished in previous analyses (17). In addition, these families were typed 
with four highly polymorphic markers from the chromosome llq24- 
to-llq25-interval that contains the ROMK gene (KCNJ1) (17).
Microsatellite polymorphisms were amplified by PCR, using for­
ward primers labeled at the 5' end with y32?. PCR reactions were 
performed in a 25-fxl volume containing 1.5 mM MgCl2, 5 mM Tris, 
pH 8.3, 50 mM KC1, 20 pmol of each primer, and 0.5 U of Taq 
polymerase. After an initial denaturation step at 95.6°C for 10 s, PCR 
was conducted for 20 cycles with denaturation at 93°C for 35 s, 
annealing at 63°C for 40 s (—0.5°C per cycle), and extension at 72°C 
for 1 min. The product was denatured for 8 s at 95°C. This was 
Mowed by 10 cycles of denaturation at 93°C for 35 s, annealing at 
56°C for 40 s, and extension at 72°C for 1 min. The reaction was
completed with a final elongation step at 72°C for 5 min. Amplified 
products were separated on a 6% polyacrylamide gel run under 
denaturing conditions. The results were analyzed using autoradiogra­
phy. Haplotypes were constructed from the genotype data.
Single-Stranded Conformational Polymorphism  
Analysis and DNA Analysis
Aberrant band patterns for the NKCC2 gene were sought using 
single-stranded conformational polymorphism analysis (SSCA) (22). 
Specific primer pairs that amplify the exon-intron splice sites and the
26 exons of this gene have been described (15). PCR conditions were 
optimized for each primer pair, and PCR was performed as described 
previously using genomic DNA from each family and two of the 
sporadic cases (17). Amplified products were analyzed for conforma­
tional variants by electrophoresis on a Mutation Detection Enhance­
ment nondenaturing gel at 4°C, 25°C, or both. The DNA product was 
then reamplified with the same primer pair from genomic DNA. The 
reamplified product purified with the Qiaex II gel extraction kit 
(Qiagen, Santa Clarita, CA) and direct sequencing was performed 
using a dye-terminator cycle sequencing method on an ABI 377 
automated DNA sequencer (Applied Biosystems), In each variant, the 
DNA sequence was confirmed by sequencing both strands.
Results
Clinical Phenotype
A cohort of four families and 14 sporadic cases with ante­
natal Bartter’s syndrome have been identified in Costa Rica 
over a 22-yr period (20). The four families and three sporadic 
cases were available for genetic analysis (Table 1). No history 
of consanguinity was elicited from any of the available parents. 
In all patients, pregnancy was complicated by polyhydramnios, 
and seven of the nine patients were born prematurely. Six 
patients presented for evaluation within the first year of life, 
but the age at diagnosis was quite variable in the remaining 
three patients. However, all affected children had experienced 
recurrent episodes of vomiting and dehydration, dating from 
the first few weeks of life (20). The phenotype in this cohort of 
children was also remarkable for a peculiar facies (7 of 9),
Table L Clinical phenotype of the Costa Rican patients
Group PatientNo.
Gestational 
Age (wk)
Age at 
Diagnosis 
(mo)
Peculiar
Facies Strabismus
Sensorineural
Deafness11
Hypercalciuria/
Nephrocalcinosis
Families
AB.CR1 1 34 53 + ----- — +
2 39 4 + — NT
AB.CR2 3 35 27 + + -b
4 34 9 — + -----
AB.CR3 5 29 8 + + + +
AB.CR4 6 30 6 + — NT
Sporadic cases
AB.CRS1 7 40 118 + —
AB.CRS2 8 29 6 + — NT +
AB.CRS3 9 32 5 — + ----- +
a Sensorineural hearing loss was diagnosed by audiogram testing and coded as either + , present; absent; or NT, not tested.
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strabismus (5 of 9), and evidence of sensorineural hearing loss 
by audiogram testing (2 of 9).
At presentation, all patients had hypokalemic metabolic al­
kalosis, hyposthenuria, and failure to thrive, with growth pa­
rameters less than the third percentile for age (20). Hyper- 
calciuria with associated sonographic evidence of nephrocal- 
cinosis was demonstrated in seven children. The other two 
children had evidence of nephrocalcinosis but normal urine 
calcium excretion. Renal function was well preserved in all but 
one patient (patient 1), who developed renal insufficiency and 
progressed to end-stage renal disease (ESRD) by 16 yr of age. 
Although the development of tubulointerstitial disease leading 
to a progressive decline in renal function has been described 
both in patients treated with long-term indomethacin and in 
patients with classic Banter’s syndrome (23,24), this patient 
was not treated with indomethacin, and the etiology of her 
end-stage renal disease remains unexplained.
Genotype Analysis
To determine whether the NKCC2 gene was the disease 
susceptibility locus in our Costa Rican cohort, we typed mark­
ers tightly linked to the NKCC2  locus on chromosome 15 in the 
four families. Haplotypes constructed for these pedigrees are 
consistent with linkage to the NKCC2  locus, either because two 
affected siblings share the same haplotypes (AB.CR1 and 
AB.CR2) or because the affected child and the unaffected 
siblings have different haplotypes (AB.CR3 and AB.CR4) 
(Figure 1). For the three micro satellite markers, D15S143- 
D15S123-D15S126, a common haplotype (1-4-4) is observed 
in this cohort. In families AB.CR2 and AB.CR4, the affected 
children are homozygous for the same haplotype, and the 
affected child in a family AB.CR3 is heterozygous for this 
haplotype. The three sporadic cases were also typed with these 
markers. AB.CRS1 (patient 7) is homozygous for D15S143 
and D15S123, the first two markers of this common haplotype. 
Of note, these markers are contained on the same YAC as the 
NKCC2 gene. AB.CRS2 (patient 8) is heterozygous for the 
common 1-4-4 haplotype. In the absence of consanguinity in 
any of the test families, these data indicate the presence of an 
ancestral haplotype in this population and suggest that a single 
mutant allele introduced by a single founder may predominate.
It is also interesting to note that the affected child in family
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Figure 1. Pedigiees and haplotypes of Costa Rican antenatal Bartter’s syndrome families with apparent linkage to the chromosome 15
bumetanide-sensitive Na-K-2C1 cotransporter (NKCC2) interval. For each child, the paternal chromosome is represented on the left and the
maternal chromosome on the right. For the three microsatellite markers, D15S143-D15S123-D15S126, the common haplotype (1-4-4) is framed
with a solid box. In family AB.CR3, an apparent recombination event in the paternal haplotype of an unaffected sibling is indicated by an oval.
In family AB.CR4, the maternal haplotypes are indicated by italics. An encircled question mark with a slash through it denotes a deceased infant 
with unknown phenotype. Not all family members are represented in family AB.CR1 or family AB.CR4.
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AB.CR3 and the sporadic case, AB.CRS2 (patient 8), are 
heterozygous for the 1-3-2 haplotype. However, the possibility 
that this haplotype may contain a second founder mutant allele 
is somewhat diminished by the fact that the asymptomatic
mother in family AB.CR2 carries both the 1-4-4 and the 1-3-2
1
haplotypes.
Mutational Analysis o f the NKCC2 Gene
These haplotype data prompted a search for mutations in 
NKCC2. Sets of primers designed from intronic sequences of 
NKCC2 (15) were used to amplify the coding sequence for 
exons 1 through 26 from genomic DNA of our test cohort. The 
amplified products were analyzed by SSCA. Aberrant SSCA 
patterns were detected for exon 14 in three of the families 
(AB.CR2, AB.CR3, and AB.CR4) and in two sporadic cases. 
The affected children in the AB.CR2 and AB.CR4 families are 
homozygous for this aberrant SSCA band, as is the sporadic 
case, AB.CRS1 (patient 7). The affected child in AB.CR3 and 
the sporadic case, AB.CRS2 (patient 8), are heterozygous for 
this exon 14 variant band. In each individual with this variant 
band, sequence analysis revealed a G ^  A substitution at 
position 1894 that introduces a premature stop in codon W625 
(Figure 2). Because this W625X mutation truncates nearly half 
of the NKCC2 gene product, we would predict that the cotrans­
porter protein is not functional in W625X homozygotes.
Of note, the W625X mutation has not been detected in a 
cohort of more than 50 other antenatal Bartter’s syndrome 
patients from European, American, North African, or Turkish 
populations (International Collaborative Study Group for Bar- 
tter-like Syndromes, unpublished data).
Discussion
Over 22 yr, 20 children with antenatal Bartter’s syndrome 
have been identified and characterized at the Hospital Nacional 
de Ninos, the only pediatric tertiary referral center in Costa 
Rica. The patient data support the autosomal recessive mode of
inheritance proposed by others (2,10,12,25). Although the 
worldwide prevalence of antenatal Bartter’s syndrome has not 
been established, the case frequency appears to be relatively 
high in the Costa Rican population. If the number of antenatal 
Bartter’s syndrome cases is compared with the total number of 
live births during this interval, the incidence would be 1.2 cases 
per 100,000 live births per year. However, if only preterm 
births are considered, the incidence would be 25.4 cases per 
100,000 births per year. Clinical observation suggests that 
consanguinity is not prevalent in Costa Rica. Therefore, other 
mechanisms need to be invoked to explain this relatively high 
incidence. As an alternative explanation, we speculate that 
because the population of Costa Rica is small and genetically 
isolated (26), antenatal Bartter’s syndrome within this isolated 
population is genetically homogeneous. That is, the disorder 
may involve only one disease susceptibility gene. In isolated 
populations, the incidence of relatively rare, recessive disor­
ders tends to be more enriched than in other populations (27).
The haplotype data and mutational analyses presented in this 
report support the hypothesis that antenatal Bartter’s syndrome 
in Costa Rica is genetically homogeneous. Furthermore, these 
data confirm that mutations in the gene encoding the bumet- 
anide-sensitive Na-K-2C1 cotransporter (NKCC2) underlie the 
pathogenesis of antenatal Bartter’s syndrome in different pop­
ulations. We have identified a predominant NKCC2  mutation 
that accounts for eight of the 14 mutant alleles in this cohort. 
This mutation introduces a premature stop in codon W625 of 
the NKCC2 gene. The W625X mutant allele is contained on a 
single haplotype, suggesting that the mutation was introduced 
into the population by a single founder. In other words, in our 
test cohort, most of the affected children apparently have a 
single common ancestor.
Although we have screened all 26 NKCC2 exons by SSCA 
in this cohort, we have not identified any additional mutations 
in this cohort. This phenomenon has precedence. Recent re­
ports of mutational analysis in X-linked Alport’s syndrome
Control Heterozygote
Asn Trp Trp
A A C T G Q T Ö Ü
Trp
Asn st0p Trp
A A C T S  A TO Q
Patient
Asn Stop
A A C T G  A T O  Q
C P H
Figure 2. Mutational analysis in the NKCC2 gene in the Costa Rican patients. Aberrant band patterns were identified by single-stranded 
conformational polymorphism analysis and evaluated by DNA sequence analysis. On the right, a representative autoradiogram is shown for a 
normal control (C), a homozygote (P) (patient 4), and her heterozygous mother (H) (family AB.CR2). On the left, the corresponding sequence 
data (sense strand) are shown for each individual. The G —» A substitution in codon W625 results in the premature truncation of the NKCC2  
cotransporter protein.
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have demonstrated that SSCA screening resulted in a mutation 
detection rate of only 50% (28,29). Given that patient 5 and 
patient 8 are both heterozygous for the W625X mutation, we 
speculate that these children are compound heterozygotes for 
other, as yet unidentified, NKCC2 mutation(s). Although we 
cannot confirm that defects in NKCC2 underlie the basis of 
antenatal Bartter’s syndrome in family AB.CR1 and patient 9, 
haplotype analysis in AB.CR1 has excluded linkage to KCNJ1, 
which encodes the ROMK channel protein, and no mutations 
were detected in the coding region of KCNJ1 in either family 
AB.CR1 or patient 9 (17) (data not shown).
The Costa Rican patients share a number of characteristics 
with the antenatal Bartter’s syndrome patients reported previ­
ously in the literature (reviewed in reference 20). A primary 
defect in the NKCC2  gene could account for many of these 
common clinical features. However, in addition to these shared 
pathophysiologic characteristics, the Costa Rican patients also 
have a number of relatively unique features that are not readily 
explained by NKCC2 mutations (Table 1). The most remark­
able phenotype in these patients is their peculiar facies. Al­
though described previously (30), this facies is so characteristic 
in the Costa Rican cohort that its presence in a Costa Rican 
child with failure to thrive strongly suggests the diagnosis of 
antenatal Bartter’s syndrome (20). Strabismus and sensorineu­
ral hearing loss are also unusually frequent in this Costa Rican 
cohort. Of the nine patients who underwent genetic analysis, 
five had strabismus. However, children homozygous for the 
W625X mutation (patients 3, 4, 6 , and 7) were not concordant 
for strabismus. Two patients (patients 3 and 5) had sensorineu­
ral hearing loss. Because sensorineural hearing loss can com­
plicate the pharmacologic inhibition of Na-K-CI cotransport 
with bumetanide or furosemide (31), it is tempting to speculate 
that defects in NKCC2 could be responsible for the hearing loss 
in these patients. However, a recent study has established that 
the NKCC1 gene product, and not NKCC2-Zncoded protein, is 
responsible for Na-K-Cl cotransport in the inner ear (32). 
Moreover, in the current study, two sisters (patients 3 and 4) 
were homozygous for the W625X mutation, but discordant for 
hearing loss.
Finally, the Costa Rican patients have a milder clinical 
course than other antenatal Banter’s syndrome patients with 
NKCC2  mutations (5,8,9,19). We and others have proposed 
that defective mTAL chloride transport is central to the patho­
genesis of antenatal Bartter’s syndrome. Because the common 
W625X mutation is predicted to truncate nearly half of the 
NKCC2  gene product, the mutant allele itself does not readily 
account for the milder disease phenotype. We speculate that 
there are other genetic or physiologic factors in the Costa Rican 
cohort that attenuate the consequences of the mTAL transport 
defect. These children may partially compensate by expressing 
an alternative transport protein in the mTAL or by differen­
tially upregulating NaCl transport in more distal nephron seg­
ments. In addition, it is noteworthy that these children did not 
require indomethacin treatment, which has been well estab­
lished as a life-saving therapeutic intervention in other antena­
tal Bartter’s syndrome patients (20). This observation may 
indicate that either prostaglandin E2 stimulation itself or the
physiologic response to prostaglandin E2 is relatively blunted 
in the Costa Rican children. Investigations are under way in 
animal models that may elucidate these and other potential 
compensatory mechanisms (S. C. Hebert, personal communi­
cation). These data could provide important insights for de­
signing targeted therapeutic interventions for this often devas­
tating disease.
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